Ongoing progress in BRAF-mutated non-small cell lung cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36331404/
Activating BRAF mutations are detected in 1.5% to 4.5% of patients with non-small cell lung cancer (NSCLC). These mutations involve the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway, and affect proliferation,...
Relevance: First-generation BRAF inhibitors are not active in the class II and III BRAF mutations that form the other half of BRAF mutations in NSCLC. New RAF inhibitors are being investigated in early trials. Novel treatment combinations, particularly with immune checkpoint inhibitors, are also underway. Patient referral to expert centers and...
-
Albert Dekker3yrobviously with Braf inhibitors it would be better
Comparison of 22C3-PD-L1 Expression Between Paired Tumor... : Applied Immunohistochemistry & Molecular Morphology
ion. A total of 460 paired paraffin blocks of surgical NSCLC specimens were analyzed using the 22C3-PD-L1 assay. PD-L1 expression between 2 paired paraffin blocks was calculated using 3 classification...
Conclusions: In cases that harbored different morphology in different paraffin blocks, the dual-block immunohistochemistry assessment method is recommended due to the intratumoral heterogeneity.
-
Albert Dekker3yrWe know that tumors are heterogeneous but in real life how many blocks will you test
BIR Publications
Source : https://www.birpublications.org/doi/10.1259/bjr.20210270
Therapy and prognosis of several solid and hematologic malignancies, including non-small cell lung cancer (NSCLC), have been favourably impacted by the introduction of immune checkpoint inhibitors (ICIs). Their mechanism of...
Conclusions: We will explore the role of radiomics in the setting of ICI-treated patients.
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36331328/
Tumor immune microenvironmental marker expression, especially CD8/PD-L1 or CD68/PD-L1 co-expression, was associated with the efficacy of PD-1 blockade plus chemotherapy as first-line treatment in patients with advanced NSCLC.
Summary: Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy
The impact of patient travel time on disparities in treatment for early stage lung cancer in California
Source : https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0272076
Background Travel time to treatment facilities may impede the receipt of guideline-concordant treatment (GCT) among patients diagnosed with early-stage non-small cell lung cancer (ES-NSCLC). We investigated the relative contribution of...
Conclusion: The benefit of GCT observed with increased travel times may be a ‘Travel Time Paradox,’ and may vary across racial/ethnic and socioeconomic groups.
-
Albert Dekker3yrobviously the further people live the harder is to get